77 related articles for article (PubMed ID: 28558940)
1. Hyperthermia enhances bortezomib-induced apoptosis in human white blood cancer cells.
Saliev T; Feril LB; Begimbetova D; Baiskhanova D; Klodzinskyi A; Bobrova X; Aipov R; Baltabayeva T; Tachibana K
J Therm Biol; 2017 Jul; 67():9-14. PubMed ID: 28558940
[TBL] [Abstract][Full Text] [Related]
2. Induction of Apoptosis in U937 Cells by Using a Combination of Bortezomib and Low-Intensity Ultrasound.
Saliev T; Feril LB; Ogawa K; Watanabe A; Begimbetova D; Molkenov A; Alimbetov D; Tachibana K
Med Sci Monit; 2016 Dec; 22():5049-5057. PubMed ID: 28003640
[TBL] [Abstract][Full Text] [Related]
3. Proteasome inhibitors potentiate leukemic cell apoptosis induced by the cyclin-dependent kinase inhibitor flavopiridol through a SAPK/JNK- and NF-kappaB-dependent process.
Dai Y; Rahmani M; Grant S
Oncogene; 2003 Oct; 22(46):7108-22. PubMed ID: 14562039
[TBL] [Abstract][Full Text] [Related]
4. Combination of bortezomib and daunorubicin in the induction of apoptosis in T-cell acute lymphoblastic leukemia.
Du X; Tong J; Lu H; He C; Du S; Jia P; Zhao W; Xu H; Li J; Shen Z; Wu Y; Tong J; Zhou L
Mol Med Rep; 2017 Jul; 16(1):101-108. PubMed ID: 28487980
[TBL] [Abstract][Full Text] [Related]
5. Combination of hyperthermia and bortezomib results in additive killing in mantle cell lymphoma cells.
Milani V; Lorenz M; Weinkauf M; Rieken M; Pastore A; Dreyling M; Issels R
Int J Hyperthermia; 2009 Jun; 25(4):262-72. PubMed ID: 19670095
[TBL] [Abstract][Full Text] [Related]
6. The synergistic effects of hyperthermia and anticancer drugs on induction of apoptosis.
Nakao K; Otsuki Y; Akao Y; Ito Y; Marukawa O; Tachibana S; Kawakami M; Sasaki S
Med Electron Microsc; 2000; 33(1):44-50. PubMed ID: 11810457
[TBL] [Abstract][Full Text] [Related]
7. A novel carbohydrate-based therapeutic GCS-100 overcomes bortezomib resistance and enhances dexamethasone-induced apoptosis in multiple myeloma cells.
Chauhan D; Li G; Podar K; Hideshima T; Neri P; He D; Mitsiades N; Richardson P; Chang Y; Schindler J; Carver B; Anderson KC
Cancer Res; 2005 Sep; 65(18):8350-8. PubMed ID: 16166312
[TBL] [Abstract][Full Text] [Related]
8. Bortezomib-mediated downregulation of S-phase kinase protein-2 (SKP2) causes apoptotic cell death in chronic myelogenous leukemia cells.
Iskandarani A; Bhat AA; Siveen KS; Prabhu KS; Kuttikrishnan S; Khan MA; Krishnankutty R; Kulinski M; Nasr RR; Mohammad RM; Uddin S
J Transl Med; 2016 Mar; 14():69. PubMed ID: 26956626
[TBL] [Abstract][Full Text] [Related]
9. Bortezomib enhances the therapeutic efficacy of dasatinib by promoting c-KIT internalization-induced apoptosis in gastrointestinal stromal tumor cells.
Dong Y; Liang C; Zhang B; Ma J; He X; Chen S; Zhang X; Chen W
Cancer Lett; 2015 May; 361(1):137-46. PubMed ID: 25737303
[TBL] [Abstract][Full Text] [Related]
10. Bortezomib-mediated down-regulation of telomerase and disruption of telomere homeostasis contributes to apoptosis of malignant cells.
Ci X; Li B; Ma X; Kong F; Zheng C; Björkholm M; Jia J; Xu D
Oncotarget; 2015 Nov; 6(35):38079-92. PubMed ID: 26472030
[TBL] [Abstract][Full Text] [Related]
11. Mcl-1 downregulation sensitizes glioma to bortezomib-induced apoptosis.
Zhang Y; Zhu X; Hou K; Zhao J; Han Z; Zhang X
Oncol Rep; 2015 May; 33(5):2277-84. PubMed ID: 25812695
[TBL] [Abstract][Full Text] [Related]
12. Bortezomib induces apoptosis in T lymphoma cells and natural killer lymphoma cells independent of Epstein-Barr virus infection.
Iwata S; Yano S; Ito Y; Ushijima Y; Gotoh K; Kawada J; Fujiwara S; Sugimoto K; Isobe Y; Nishiyama Y; Kimura H
Int J Cancer; 2011 Nov; 129(9):2263-73. PubMed ID: 21170988
[TBL] [Abstract][Full Text] [Related]
13. In vitro cytotoxic effect of proteasome inhibitor bortezomib in combination with purine nucleoside analogues on chronic lymphocytic leukaemia cells.
Duechler M; Linke A; Cebula B; Shehata M; Schwarzmeier JD; Robak T; Smolewski P
Eur J Haematol; 2005 May; 74(5):407-17. PubMed ID: 15813915
[TBL] [Abstract][Full Text] [Related]
14. Bortezomib Treatment can Overcome Glucocorticoid Resistance in Childhood B-cell Precursor Acute Lymphoblastic Leukemia Cell Lines.
Junk S; Cario G; Wittner N; Stanulla M; Scherer R; Schlegelberger B; Schrappe M; von Neuhoff N; Lauten M
Klin Padiatr; 2015 May; 227(3):123-30. PubMed ID: 25985447
[TBL] [Abstract][Full Text] [Related]
15. Bik/NBK accumulation correlates with apoptosis-induction by bortezomib (PS-341, Velcade) and other proteasome inhibitors.
Zhu H; Zhang L; Dong F; Guo W; Wu S; Teraishi F; Davis JJ; Chiao PJ; Fang B
Oncogene; 2005 Jul; 24(31):4993-9. PubMed ID: 15824729
[TBL] [Abstract][Full Text] [Related]
16. TNF potentiates anticancer activity of bortezomib (Velcade) through reduced expression of proteasome subunits and dysregulation of unfolded protein response.
Nowis D; McConnell EJ; Dierlam L; Palamarchuk A; Lass A; Wójcik C
Int J Cancer; 2007 Jul; 121(2):431-41. PubMed ID: 17373661
[TBL] [Abstract][Full Text] [Related]
17. Narrow line between benefit and harm: Additivity of hyperthermia to cisplatin cytotoxicity in different gastrointestinal cancer cells.
Cesna V; Sukovas A; Jasukaitiene A; Naginiene R; Barauskas G; Dambrauskas Z; Paskauskas S; Gulbinas A
World J Gastroenterol; 2018 Mar; 24(10):1072-1083. PubMed ID: 29563752
[TBL] [Abstract][Full Text] [Related]
18. [Effects of the phosphoinostitide-3'-kinase delta inhibitor, CAL-101, in combination with Bortezomib on mantle lymophma cells and exploration of its related mechanism].
Qu F; Xia B; Li X; Guo S; Zhang L; Tian C; Yu Y; Zhang Y
Zhonghua Zhong Liu Za Zhi; 2015 Jun; 37(6):412-7. PubMed ID: 26463142
[TBL] [Abstract][Full Text] [Related]
19. Bortezomib sensitizes human osteosarcoma cells to adriamycin-induced apoptosis through ROS-dependent activation of p-eIF2α/ATF4/CHOP axis.
Xian M; Cao H; Cao J; Shao X; Zhu D; Zhang N; Huang P; Li W; Yang B; Ying M; He Q
Int J Cancer; 2017 Sep; 141(5):1029-1041. PubMed ID: 28524233
[TBL] [Abstract][Full Text] [Related]
20. The proteasome inhibitor bortezomib acts independently of p53 and induces cell death via apoptosis and mitotic catastrophe in B-cell lymphoma cell lines.
Strauss SJ; Higginbottom K; Jüliger S; Maharaj L; Allen P; Schenkein D; Lister TA; Joel SP
Cancer Res; 2007 Mar; 67(6):2783-90. PubMed ID: 17363600
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]